Drug Profile
Research programme: metformin controlled release - Spencer Pharmaceutical
Alternative Names: Met4Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Spencer Pharmaceutical
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 24 Aug 2010 Preclinical trials in Type-2 diabetes mellitus in USA (PO)